A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma
Study of Pembrolizumab Plus Gemcitabine/Cisplatin as First-Line Therapy in Patients with Biliary Tract Carcinoma
Sponsor: Merck Sharp & Dohme LLC
Enrolling: Male and Female Patients
IRB Number: AAAS6251
U.S. Govt. ID: NCT04003636
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine whether combining the drug pembrolizumab with the standard first-line chemotherapy treatment of gemcitabine and cisplatin for biliary tract carcinoma will more effectively fight your cancer than the standard chemotherapy treatment alone. Pembrolizumab is thought to work by preventing cells within the immune system that fight tumors from dying.
This study is closed
Investigator
Susan Bates, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have advanced and/or unresectable biliary tract cancer? Yes No
Are you willing to have a tumor biopsy or provide a sample of your tumor tissue? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE